logo
Plus   Neg
Share
Email

Merck Announces Label Expansion For KEYTRUDA In Canada - Quick Facts

Merck (MRK) announced that Health Canada has expanded the label for KEYTRUDA (pembrolizumab), the company's anti-PD-1 therapy, to include approval for the treatment of metastatic non-squamous non-small cell lung cancer or NSCLC, in combination with pemetrexed and platinum chemotherapy, in adults with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.

KEYTRUDA was first approved in Canada in 2015 and currently has eight indications in a number of disease areas, including non-small cell lung cancer, classical Hodgkin lymphoma, melanoma and bladder cancer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Facebook has removed four separate networks of accounts, pages and groups for engaging in co-ordinated inauthentic behavior on Facebook and Instagram. These networks originated from Iran and Russia and primarily targeted the US, North Africa and Latin America. These networks often posted on both sides of political issues including topics like US elections, environmental issues, racial tensions. While reporting financial results for the third quarter on Tuesday, Lockheed Martin Corp. (LMT) raised its earnings and net sales guidance for the full-year 2019, and initiated net sales outlook for the full-year 2020. For fiscal 2019, the company now expects earnings of about $21.55 per share, up... Consumer goods giant Procter & Gamble on Tuesday reported a 12 percent increase in profit for the first quarter of fiscal 2020 from last year, driven by an increase in net sales and operating margin. Both revenue and core earnings per share for the quarter beat analysts' estimates. Looking ahead, the company raised its earnings and revenue growth guidance for the full-year 2020.
Follow RTT
>